Jacques Aubry

Title: Innovations in Cancer Treatment by Jacques Aubry

Introduction

Jacques Aubry is a notable inventor based in Nantes, France. He has made significant contributions to the field of cancer treatment through his innovative use of monoclonal antibodies. With a total of 2 patents, Aubry's work focuses on enhancing the specificity and efficacy of cancer therapies.

Latest Patents

Aubry's latest patents revolve around the use of monoclonal antibodies that specifically target the O-acetylated form of GD2 ganglioside. These antibodies are designed for the diagnosis and treatment of cancers where cells express the O-acetylated GD2. The invention emphasizes the importance of recognizing O-acetylated GD2 molecules expressed by tumoral cells while avoiding recognition of GD2 molecules on peripheral nerves. This specificity aims to improve diagnostic accuracy and reduce treatment toxicity. Additionally, the patents include the use of artificially modified antibodies for similar therapeutic and diagnostic purposes.

Career Highlights

Jacques Aubry is affiliated with the University of Nantes, where he continues to advance research in cancer treatment. His innovative approaches have garnered attention in the scientific community, contributing to the ongoing development of targeted therapies.

Collaborations

Aubry has collaborated with notable colleagues such as Jean-Marie Mussini and Jacques Barbet. Their combined expertise enhances the research efforts in the field of monoclonal antibodies and cancer treatment.

Conclusion

Jacques Aubry's work exemplifies the potential of targeted therapies in oncology. His innovative patents and collaborations are paving the way for more effective cancer treatments, ultimately benefiting patients worldwide.